Sirolimus as the main immunosuppressant in the early postoperative period following liver transplantation: A report of six cases and review of the literature

Transplant International

Volumn 19, Issue 12, 2006, Pages 1022-1025

  Vivarelli, Marco ^a   Vetrone, Gaetano ^a   Zanello, Matteo ^a   Barba, Giuliano La ^a   Cucchetti, Alessandro ^a   Lauro, Augusto ^a   Grazi, Gian Luca ^a   Pinna, Antonio Daniele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Immunosuppression; Liver transplantation

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; RAPAMYCIN; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; BRAIN DISEASE; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KIDNEY FUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROTOXICITY; OLIGURIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SEPSIS; SPEECH DISORDER;

AGED; CALCINEURIN; FEMALE; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; SIROLIMUS;

EID: 33750578442     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2006.00381.x     Document Type: Article

References (12)

1. Trotter JF. Sirolimus in liver transplantation. Transplant Proc 2003; 35(Suppl. 3A): 193S.
2. Chang GJ, Mahanty HD, Quan D, et al. Experience with the use of sirolimus in liver transplantation - use in patients for whom CIs are contraindicated. Liver Transpl 2000; 6: 734.
3. Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl 2003; 9: 1079.
4. Kneteman NM, Oberholzer J, Al Saghier M, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004; 10: 1301.
5. Fung J, Kelly D, Kadry Z, Patel-Tom K, Eghtesad B. Immunosuppression in liver transplantation. Beyond calcineurin inhibitors. Liver Transpl 2005; 11: 267.
6. Bartlett AS, Ramadas R, Furness S, Gane E, McCall J. The natural history of acute histologic rejection without biochemical graft dysfunction in orthotopic liver transplantation: a systematic review. Liver Transpl 2002; 12: 1147.
7. Dunkelberg JC, Trotter JF, Wachs M, et al. Sirolimus as primary immunosuppression in C is not associated with hepatic artery or wound complication. Liver Transpl 2003; 9: 463.
8. Montalbano M, Neff GW, Yamashiki N, et al. A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation 2004; 78: 264.
9. Fisher A, Seguel JM, de la Torre AN, et al. Effect of sirolimus on infection incidence in liver transplant recipients. Liver Transpl 2004; 10: 193.
10. Samonakis DN, Cholongitas E, Triantos CK, et al. Sustained spontaneous disappearance of serum HCV-RNA under immunosuppression after liver transplantation for HCV cirrhosis. J Hepatol 2005; 43: 1091.
11. Ercolani G, Grazi GL, Ravaioli M, et al. Histological recurrent hepatitis C after liver transplantation: outcome and role of retransplantation. Liver Transpl 2006; 12: 1104.
12. Watson CJ, Friend PJ, Jamieson NV, et al. Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation 1999; 67: 4.